I n n a t
© Takeda Belgium
v
© Takeda Belgium
o i o
In addition, the site continues to invest in digitalization and has an active recruitment policy, with nearly 200 staff hired in 2019 alone. “This strong growth is easily explained by the fact that 90% of patients with primary immune deficiency lack one protein, immunoglobulin G, which is purified in the Lessines plant to provide patients with lifelong treatments. In addition, the biopharma industry has estimated that, for the period 2016-2024, the annual growth rate in demand for immunological products will be at least 6.7%,” Geoffrey Pot explains.
© Takeda Belgium
n associations around the world are consulted to contribute to the assessment of Takeda's 400 top managers: they feed back on their perception of Takeda, the quality of its collaboration and partnerships with them.
h n o
“Takeda’s investments, strategy and marketing are always patientfocused. This commitment translates into finding solutions in cooperation with patients, far beyond the simple provision of treatment,” explains Laurent Henaux. In a similar vein, the company has set up a support and services program to help patients in their daily lives. To drive this patient-centric way of thinking it has developed the “In Their Shoes” application to allow its employees and health care professionals (nurses, gastroenterologists etc.) to empathise with the experiences of patients suffering from Crohn's disease and other inflammatory bowel diseases. The application includes simulation exercises that make it possible to recreate the everyday constraints of the pathology as realistically as possible. This application should soon be available for other conditions.
c
In this way, Takeda is continuously strengthening its commitment to supporting patients and building with them the best possible quality of life, for today and tomorrow. This ambition is firmly based on the contributions of employees, who create value but also a sense of meaningfulness, in accordance with patient needs and expectations. All in all, a winning corporate culture!
At the service of patients
T e
Working perfectly alongside Takeda's plant in Social Circle, Georgia (USA), Takeda's Lessines plant is currently finalising a major investment in a new purification unit to manufacture a new plasma protein. And that's not all: the plant is investing in continuous improvement (quality, compliance, shorter production times and delivery of crucial products classified in the “life savers” category) and in increasing its capacity with regard to purification, aseptic filling and packaging.
l o g
Takeda Belgium s.c.a. | c.v.a. Leonardo Da Vincilaan, 7 - 1930 Zaventem Tel.: +32 2 464 06 11 Email: be-info@takeda.com http://www.takeda.be 97
y
In relation to the same diseases, Takeda has co-created with the patient associations blogs that give patients a voice: these life stories allow solutions to be shared in a spirit of mutual support with family and friends. With 30,000 affected persons in Belgium, these blogs have 120,000 unique visitors each year. This is proof that the interest and added value is there for patients and their families. And there is more: every year, 150 patient
